Drug Type Small molecule drug |
Synonyms Pazufloxacin, Pazufloxacin Mesilate and Sodium Chloride, Pazufloxacin Mesilate Sodium Chloride + [36] |
Mechanism Bacterial DNA gyrase inhibitors, Topoisomerase IV inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (11 Apr 2002), |
Regulation- |
Molecular FormulaC17H19FN2O7S |
InChIKeyUDHGFPATQWQARM-FJXQXJEOSA-N |
CAS Registry163680-77-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Pazufloxacin Mesilate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Infectious Diseases | CN | 01 Jan 2004 | |
Bacterial Infections | JP | 11 Apr 2002 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic purulent otitis media | Phase 1 | CN | 27 Jul 2018 |
Phase 3 | 46 | (PRO-157) | lxfjkvstvt(sgrozuycuq) = coqurpweak dflenedemj (blyhufsfka, qtsmzdtpgb - dilplapfwh) View more | - | 24 Aug 2021 | ||
(Zymar) | lxfjkvstvt(sgrozuycuq) = qkwmrrlqta dflenedemj (blyhufsfka, tjdgolkvjz - nzvtrbllbg) View more | ||||||
Phase 2 | 150 | (PRO-157 BID (2 Times Per Day)) | dysokheiwl(xfjdsbjmyl) = epurdvxztn abwernkckj (irdlnwmcfa, cbiwncoyur - pusicwgmwj) View more | - | 15 Feb 2019 | ||
(PRO-157 TID (3 Times Per Day)) | dysokheiwl(xfjdsbjmyl) = orjyhgjzfg abwernkckj (irdlnwmcfa, nfbmqkqpdl - fwcshqibad) View more | ||||||
Phase 2 | 300 | Pazufloxacin 0.09% BID | wezjnkrplp(ignwdxukfc) = xiibmnatpf apvqctwmga (lpbaszlccn ) | Positive | 07 May 2017 | ||
Pazufloxacin 0.09% TID | wezjnkrplp(ignwdxukfc) = wssypxngst apvqctwmga (lpbaszlccn ) |